A5000669625- Circular RNAs in diseases
- MXene and MAX Phase Materials
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Research Studies
- Ferroptosis and cancer prognosis
- Immunotherapy and Immune Responses
- Cancer, Lipids, and Metabolism
- interferon and immune responses
- Superconductivity in MgB2 and Alloys
Jiangsu Cancer Hospital
2021-2024
Nanjing Medical University
2021-2023
Second Affiliated Hospital of Nanjing Medical University
2023
Background Hepatocellular carcinoma (HCC) is the most common pathological type of primary liver cancer. The lack prognosis indicators one challenges in HCC. In this study, we investigated combination tertiary lymphoid structure (TLS) and several systemic inflammation parameters as a indicator for Materials Methods We retrospectively recruited 126 postoperative patients with paraffin section was collected TLS density assessment. addition, from peripheral blood samples. evaluated prognostic...
Background PD-1 inhibitors have been routinely used in the treatment of advanced non-small cell lung cancer (NSCLC), and demonstrated to significantly improve survivorship when combining with other conventional therapies, such as chemotherapy anti-angiogenesis therapy. PD-L1 is most commonly biomarker select benefiting groups, while not all patients high expression benefit from immunotherapy. Therefore, identifying prognostic predictive biomarkers, including peripheral blood indexes,...
<p>5. cEMSY promotes ICD-driven anti-tumor immune surveillance.</p>
<p>Supplementary Fig. 3. cEMSY induces ICD in vitro.</p>
<div>Abstract<p>Immunogenic cell death (ICD) induces an active immune response. Activating ICD represents a potential approach to boost the antitumor activity of immunotherapy, highlighting need identify effective and safe inducers. In this study, we identified conserved, ICD-related circular RNA cEMSY by systematically screening models induced multiple stressors in lung adenocarcinoma. triggered adenocarcinoma cells both <i>in vitro</i> vivo</i>, leading...
<p>Supplementary Fig. 11. cEMSY expression level affects patient prognosis in multiple clinical cancer cohorts.</p>
<p>Supplementary Fig. 4. cEMSY knockout abrogates the ability of cellular stressors to induce ICD.</p>
<p>Supplementary Fig. 2. Characteristics of cEMSY circRNA and expression profiles in LUAD.</p>
<p>Supplementary Fig. 6. In vitro and in vivo characterization of designed circRNA.</p>
<p>Supplementary Fig. 9. mtDNA mediates the activation of ICD induced by cEMSY in vivo.</p>
<p>Supplementary Fig. 8. cEMSY activates antiviral immune signaling.</p>
<p>Supplementary Fig. 7. In vitro-transcribed cEMSY combined with anti-PD-1 promotes antitumor cure.</p>
<p>Table S1-S5</p>
<p>Supplementary Fig. 10. cEMSY modulates immune responses through facilitating the translocation of TDP-43 into mitochondria.</p>
<p>Supplementary Fig. 1. Filter ICD related circRNAs.</p>
The profile of immune-related adverse events (irAEs) due to programmed death-1 (PD-1) inhibitors-based combination therapy in advanced non-small cell lung cancer (NSCLC) and its relationship with survival have not been fully described.Designed capture the spectrum irAEs explore association between clinical outcomes patients NSCLC.This retrospective single-center study included NSCLC treated PD-1 inhibitors (mainly chemotherapy) at Jiangsu Cancer Hospital.The was explored using landmark...
Abstract Immunogenic cell death (ICD) induces an active immune response. Activating ICD represents a potential approach to boost the anti-tumor activity of immunotherapy, highlighting need identify effective and safe inducers. In this study, we identified conserved, ICD-related circular RNA cEMSY by systematically screening models induced multiple stressors in lung adenocarcinoma (LUAD). triggered LUAD both vitro vivo, leading release damage-associated molecular patterns promoting T...